Around 85 percent of lung cancers are classified as non-small-cell lung cancers, or NSCLCs. Some patients with these cancers can be treated with targeted genetic therapies, and some benefit from immunotherapies -- but the vast majority of NSCLC patients have no treatment options except for chemotherapy.
